BioSpace News Archive

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etiologies of endogenous Cushing’s syndrome (hypercortisolism).

INmune Bio, Inc. today announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price.

Panbela Therapeutics, Inc. today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025.

Waters Corporation introduced new GTxResolve Premier Size Exclusion Chromatography 1000Å 3-micron Columns.

Rejuvenate Bio today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Intellistem, Inc today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 10:30AM (Local Time -PST). Bill St John, CEO of Intellistem Inc. will be hosting the presentation and answering questions at the conclusion.

FSD Pharma Inc provides an update by way of a news release issued by Celly Nutrition Corp. and its launching of unbuzzd, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body’s natural processes for metabolizing alcohol and promoting alertness.

Natera, Inc. today announced that it has passed a significant milestone with the publication of more than 200 peer-reviewed papers highlighting Natera’s technology in the scientific literature.

Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, announced the closing of a $40M Series A financing round.

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.